AI assistant
TRIVARX LTD — Capital/Financing Update 2025
Dec 18, 2025
65950_rns_2025-12-18_f1382f47-90a8-4c30-bcd2-0185280afe7f.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
ASX ANNOUNCEMENT
==> picture [123 x 44] intentionally omitted <==
19 December 2025
Notice under Section 708A of the Corporations Act
Perth, Australia, and Minneapolis, USA: TrivarX Limited (‘the Company’ ) (ASX: TRI) hereby gives this notice under section 708A(5)(e) of the Corporations Act 2001 (Cth) (“Act”).
The Company has issued 437,725,337 ordinary fully paid shares at an issue price of $0.008 per share (“ Issued Shares ”) pursuant to the Placement announced on 16 October 2025 and approved by shareholders at a general meeting held on 12 December 2025.
In accordance with section 708A(5)(e) of the Act, the Company gives notice that:
-
the Issued Shares were issued without disclosure to investors under Part 6D.2 of the Act;
-
as at the date of this notice, the Company has complied with the provisions of Chapter 2M of the Act, as they apply to the Company and sections 674 and 674A of the Act; and
-
as at the date of this notice there is no information that is ‘excluded’ information within the meanings of section 708A(7) and 708A(8) of the Act, being information:
-
a) that has been excluded from a continuous disclosure notice in accordance with the ASX Listing Rules;
-
b) that investors and their professional advisers would reasonably require for the purposes of making and informed assessment of:
-
i. the assets and liabilities, financial position and performance, profits and losses and prospects of the Company; or
-
ii. the rights and liabilities attaching to the Securities.
-
This announcement is authorised for release by the Board of Directors of TrivarX Limited.
ENDS
Investor Enquiries:
Henry Jordan – Six Degrees Investor Relations [email protected] +61 431 271 538
About TrivarX Limited:
TrivarX (ASX: TRI) (OTCPINK: MDBIF) is a mental health technology company pioneering the use of objective measures to aid in the early detection and screening of mental health conditions. The Company was founded in Australia, with offices located in Perth (WA) and Minneapolis (MN, USA). TrivarX is listed on the Australian Securities Exchange Ltd and trades on the OTCQB Venture Market. Investors can find additional information on www.otcmarkets.com and www.asx.com.au
TrivarX Limited (A.B.N. 58 008 130 336) 647 Beaufort Street, Mount Lawley, WA 6050